Edurne Arriola researcher
Arriola, Edurne
VIAF ID: 305882972 (Personal)
Permalink: http://viaf.org/viaf/305882972
Preferred Forms
-
- 100 1 _ ‡a Arriola, Edurne
- 100 0 _ ‡a Edurne Arriola ‡c researcher
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry | |
Accurate Identification of Predictive Biomarkers of Response to Targeted Therapies in Lung Cancer With Next Generation Sequencing | |
ALK status in a primary lung tumour and metachronous metastases. | |
Angiopoietin-2 is a negative prognostic marker in small cell lung cancer. | |
Aromatase inhibitors and male breast cancer. | |
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study | |
Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients. | |
Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab. | |
Case Report: CD103+CD8+ lymphocytes characterize the immune infiltration in a case with pseudoprogression in SqNSCLC. | |
CD274 | |
CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patients. | |
Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. | |
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. | |
Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS. | |
A complex deletion/insertion on exon 19 of the EGFR gene predicts response to gefitinib. | |
Cutaneous recall phenomenon with vinorelbine | |
Early Onset Pulmonary Toxicity With Lorlatinib in a Patient With Previous Pulmonary Toxicity From Brigatinib | |
EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma | |
EGFR-Mutant Lung Adenocarcinoma Mimicking a Pneumonia. | |
Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples. | |
Imaging techniques contribute to increased surgical rescue of relapse in the follow-up of colorectal cancer | |
Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control. | |
Immunotherapy is Here to Stay: A New Treatment Paradigm in Lung Cancer | |
Impacto del tratamiento de segunda línea en los pacientes con cáncer de pulmón de célula no pequeña (CPCNP) | |
Infliximab for IPILIMUMAB-Related Colitis--Letter | |
Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer? | |
Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus. | |
Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel | |
MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines | |
[Metastatic intestinal perforation secondary to a primary lung tumour] | |
Methylation status of IGFBP-3 as a useful clinical tool for deciding on a concomitant radiotherapy. | |
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. | |
Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma | |
Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer. | |
Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer | |
Response to neoadjuvant therapy for rectal cancer: influence on long-term results. | |
ROS1 copy number alterations are frequent in non-small cell lung cancer | |
Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer | |
Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer. | |
TG4010: a vaccine with a therapeutic role in cancer | |
Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer | |
[Two cases of pituitary metastases as initial presentation form of small cell lung cancer] | |
Two rare exon 21 EGFR mutations in patients treated with gefitinib. |